立丞药业

Licheng Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the development of innovative small molecule drugs. The company focuses on addressing unmet medical needs in oncology and immunology through the discovery of highly selective inhibitors. Its lead candidate, LC-801, is a selective CDK2 inhibitor currently in clinical trials for advanced solid tumors. Additionally, the company is advancing LC-101, a TYK2 inhibitor for autoimmune disorders such as psoriasis. Licheng leverages a proprietary drug discovery platform to identify and optimize novel chemical entities with superior pharmacological profiles. The company is supported by top-tier venture capital investors, including Qiming Venture Partners and IDG Capital.